Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: Epoetin beta

First Posted Date: 2016-07-11

Last Posted Date: 2016-07-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 122

Registration Number: NCT02827266

A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Atezolizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2016-07-07

Last Posted Date: 2023-01-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 120

Registration Number: NCT02825940

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳
Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou City, China

and more 4 locations

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: RO5545965

First Posted Date: 2016-07-06

Last Posted Date: 2017-06-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 33

Registration Number: NCT02824055

Locations: 🇺🇸
CNS Network, Garden Grove, California, United States
🇺🇸
St Louis Clinical Trials, Saint Louis, Missouri, United States
🇺🇸
Parexel California Clinical Trials Medical Group, Glendale, California, United States

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

Phase 1

Completed

Conditions: Castrate-Resistant Prostate Cancer

Interventions: Drug: Atezolizumab
Drug: Radium-223 Dichloride

First Posted Date: 2016-06-28

Last Posted Date: 2019-09-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 45

Registration Number: NCT02814669

Locations: 🇺🇸
Mayo Clinic - Minnesota, Rochester, Minnesota, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, Commack, New York, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 14 locations

A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Drug: Docetaxel

First Posted Date: 2016-06-27

Last Posted Date: 2023-01-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 565

Registration Number: NCT02813785

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China
🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Affiliated Hospital of Bengbu Medical College, Bengbu, China

and more 35 locations

Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2016-06-22

Last Posted Date: 2016-10-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 850

Registration Number: NCT02809833

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Phase 3

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: Carboplatin
Drug: Atezolizumab
Drug: Gemcitabine
Other: Placebo
Drug: Cisplatin

First Posted Date: 2016-06-21

Last Posted Date: 2024-04-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1213

Registration Number: NCT02807636

Locations: 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺
Lyell McEwin Hospital, Adelaide, South Australia, Australia
🇨🇦
Dr. Georges L. Dumont University Hospital Centre, Moncton, New Brunswick, Canada

and more 221 locations

HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

Phase 3

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Peginterferon alfa-2a

First Posted Date: 2016-06-20

Last Posted Date: 2016-10-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 81

Registration Number: NCT02806505

A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Other Biologics
Drug: Tocilizumab

First Posted Date: 2016-06-13

Last Posted Date: 2023-01-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 48950

Registration Number: NCT02797769

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Drug: Emicizumab

First Posted Date: 2016-06-10

Last Posted Date: 2021-06-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 88

Registration Number: NCT02795767

Locations: 🇺🇸
Rush Medical Center, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Michigan; Pediatrics, Detroit, Michigan, United States
🇺🇸
North Shore/Long Island Jewish PRIME; Pediatric Hematology/Oncology & Stem Cell Transplantation, New Hyde Park, New York, United States

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy